Research programme: non-catalytic site HIV integrase inhibitors - Gilead

Drug Profile

Research programme: non-catalytic site HIV integrase inhibitors - Gilead

Alternative Names: GS 9695; GS 9822; Non-catalytic site HIV integrase inhibitors - Boehringer Ingelheim

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Developer Gilead Sciences
  • Class Anti-infectives; Antivirals
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 13 Feb 2017 Adverse events, pharmacodynamic data and pharmacokinetic data from preclinical study in HIV-infections presented at the 24th Conference on Retroviruses and Opportunistic Infections (CROI-2017)
  • 13 Feb 2017 Preclinical development in HIV-infections is ongoing in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top